作者: Lanying Du , Shibo Jiang , Shibo Jiang , Xiaojie Zhu , Lu Lu
DOI: 10.3978/J.ISSN.2072-1439.2013.06.06
关键词:
摘要: A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with mortality rate of 10%. Reports recent outbreaks SARS-like disease by Middle East (MERS-CoV) have raised serious concerns possible reemergence SARS-CoV, either laboratory escape or the presence natural reservoir. Therefore, development effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that receptor-binding domain (RBD) in S1 subunit SARS-CoV spike (S) protein most important target for developing vaccine. In particular, RBD S contains critical neutralizing (CND), which able to induce highly potent antibody response cross-protection against divergent strains. Furthermore, RBD-based vaccine expected be safer than other may Th2-type immunopathology. This review will discuss key advances possibility using similar strategy develop MERS-CoV.